Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Pharmather Hldgs Ltd
(CSE:
PHRM
)
0.2300
UNCHANGED
Official Closing Price
Updated: 3:59 PM EDT, Aug 15, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Pharmather Hldgs Ltd
PharmaTher’s Sairiyo Therapeutics Submits Clinical Trial Application for Phase 1 Study of Patented Reformulated Cepharanthine
May 15, 2024
From
PharmaTher Holdings Ltd.
Via
GlobeNewswire
PharmaTher Announces Assigned FDA Approval Goal Date of its Priority Original Abbreviated New Drug Application for Ketamine
May 10, 2024
The FDA Assigned Goal Date is October 29, 2024
From
PharmaTher Holdings Ltd.
Via
GlobeNewswire
PharmaTher’s Sairiyo Therapeutics Completes Clinical and Regulatory Package for Phase 1 Study of Patented Reformulated Cepharanthine
May 01, 2024
From
PharmaTher Holdings Ltd.
Via
GlobeNewswire
PharmaTher Provides Update of its Priority Original Abbreviated New Drug Application for Ketamine
April 18, 2024
From
PharmaTher Holdings Ltd.
Via
GlobeNewswire
PharmaTher Provides Update of its Priority Original Abbreviated New Drug Application for Ketamine
April 16, 2024
From
PharmaTher Holdings Ltd.
Via
GlobeNewswire
Revive Therapeutics Provides Update on Psilocybin Clinical Study for Methamphetamine Use Disorder
April 02, 2024
From
Revive Therapeutics Ltd.
Via
GlobeNewswire
PharmaTher’s Sairiyo Therapeutics Inc. Advances Clinical Development of Patented Reformulated Cepharanthine for Phase 1 Study in Australia
February 21, 2024
From
PharmaTher Holdings Ltd.
Via
GlobeNewswire
PharmaTher Provides Update of its Priority Original Abbreviated New Drug Application for Ketamine
February 12, 2024
From
PharmaTher Holdings Ltd.
Via
GlobeNewswire
PharmaTher Provides Update for Expected FDA Approval of Ketamine
January 10, 2024
Assigned FDA approval goal date of April 29, 2024, is still on track
From
PharmaTher Holdings Ltd.
Via
GlobeNewswire
PharmaTher Announces FDA Acceptance, As a Priority Original Abbreviated New Drug Application, for KETARX™ (Ketamine)
September 27, 2023
From
PharmaTher Holdings Ltd.
Via
GlobeNewswire
PharmaTher Submits Priority Original Abbreviated New Drug Application for KETARX™ (Ketamine) to the FDA
September 06, 2023
From
PharmaTher Holdings Ltd.
Via
GlobeNewswire
PharmaTher Announces Positive Research Results for PharmaPatch™ with N,N-dimethyltryptamine (DMT) and Strategic Investment into Sairiyo Therapeutics
July 18, 2023
From
PharmaTher Holdings Ltd.
Via
GlobeNewswire
PharmaTher Initiates Filing of Abbreviated New Drug Application for KETARX™ (racemic ketamine) to the FDA
June 27, 2023
Expected FDA approval for KETARX™ (racemic ketamine) via the ANDA pathway in Q1-2024 and commercial launch in Q2-2024
From
PharmaTher Holdings Ltd.
Via
GlobeNewswire
PharmaTher and Vitruvias Enter Into Collaboration Agreement for Commercialization of KETARX™ (racemic ketamine) in the U.S.
June 20, 2023
Expected FDA approval for KETARX™ (racemic ketamine) via the ANDA pathway in Q1-2024 and commercial launch in Q2-2024
From
PharmaTher Holdings Ltd.
Via
GlobeNewswire
PharmaTher Holdings Provides Corporate Update
June 12, 2023
From
PharmaTher Holdings Ltd.
Via
GlobeNewswire
PharmaTher Holdings Submits Fast Track Application to FDA for KETARX™ (Ketamine) for the Treatment of Parkinson’s Disease
May 02, 2023
From
PharmaTher Holdings Ltd.
Via
GlobeNewswire
Revive Therapeutics Advances MDMA Transdermal Patch Development with Purchase of MDMA Supply from PharmAla Biotech
April 03, 2023
From
Revive Therapeutics Ltd.
Via
GlobeNewswire
PharmaTher Holdings Announces Update of Type C Meeting with the FDA for KETARX™ (Ketamine) in Parkinson’s Disease
March 29, 2023
From
PharmaTher Holdings Ltd.
Via
GlobeNewswire
PharmaTher Submits FDA Meeting Package to Discuss 505(b)(2) Pathway for New Drug Application of KETARX™ (Ketamine) On-Body Pump System
February 07, 2023
From
PharmaTher Holdings Ltd.
Via
GlobeNewswire
Revive Therapeutics Secures MDMA Supply from PharmAla Biotech for MDMA Transdermal Patch Development
February 06, 2023
From
Revive Therapeutics Ltd.
Via
GlobeNewswire
PharmaTher Holdings Announces FDA Grant of Orphan Drug Designation to KETARX™ (Ketamine) for the Treatment of Rett Syndrome
February 02, 2023
From
PharmaTher Holdings Ltd.
Via
GlobeNewswire
PharmaTher Holdings Submits FDA Meeting Package to Discuss Phase 3 Program and Fast Track Designation for KETARX™ (Ketamine) in Parkinson’s Disease
February 01, 2023
From
PharmaTher Holdings Ltd.
Via
GlobeNewswire
PharmaTher Holdings Submits for FDA Orphan Drug Designation for Ketamine to Treat Rett Syndrome
January 18, 2023
From
PharmaTher Holdings Ltd.
Via
GlobeNewswire
PharmaTher Holdings Provides Update for KETARX™ (Racemic Ketamine) Development Programs and Expected Milestones for 2023
January 11, 2023
From
PharmaTher Holdings Ltd.
Via
GlobeNewswire
PharmaTher Announces FDA Orphan Drug Designation Granted to Ketamine for Prevention of Ischemia-Reperfusion Injury from Organ Transplantation
December 15, 2022
PharmaTher’s 4th FDA orphan drug designation for ketamine
From
PharmaTher Holdings Ltd.
Via
GlobeNewswire
PharmaTher Announces Poster Presentation of Positive Efficacy and Safety Data from Phase 1/2 Clinical Study of Ketamine in the Treatment of Levodopa-Induced Dyskinesia in Parkinson’s Disease at Neuroscience 2022 by the Society for Neuroscience
November 14, 2022
From
PharmaTher Holdings Ltd.
Via
GlobeNewswire
PharmaTher Enters into Exclusive Option Agreement with Case Western Reserve University to Develop and Commercialize Ketamine for Rett Syndrome
November 01, 2022
From
PharmaTher Holdings Ltd.
Via
GlobeNewswire
PharmaTher Holdings Announces Grant of U.S. Patent Covering Ketamine for Parkinson’s Disease
October 05, 2022
From
PharmaTher Holdings Ltd.
Via
GlobeNewswire
PharmaTher Provides Business Highlights and Releases Audited Annual Financials for Fiscal Year Ended May 31, 2022
September 29, 2022
From
PharmaTher Holdings Ltd.
Via
GlobeNewswire
Senate Bill Decriminalizing Psychedelics Could Help Reverse Some “War on Drugs” Impacts
September 22, 2021
Via
FinancialNewsMedia
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.